Rapport Therapeutics Insider Receives 10.9K Stock Options, Strike $10.95

Rhea-AI Filing Summary

Form 4 Overview: Rapport Therapeutics (RAPP) reported an insider transaction for director Ramiro Sanchez on 17 June 2025.

• Type of security: Non-qualified stock option (right to buy).
• Quantity: 10,925 options granted.
• Exercise price: $10.95 per share.
• Vesting: Options vest on the earlier of 17 June 2026 or the date of the next annual meeting, contingent on continued board service.
• Expiration: 17 June 2035.
• Ownership impact: Following the grant, the director now beneficially owns 10,925 derivative securities; no common shares were bought or sold.

The filing indicates a routine equity incentive award to a board member, with no immediate cash outlay or sale of shares. The transaction does not alter the company’s share count or indicate changes in strategic direction but modestly aligns the director’s compensation with long-term shareholder value.

Positive

• Grant of 10,925 stock options potentially aligns director incentives with shareholder value.

Negative

• None.

Insights

Financial Analyst

TL;DR – Routine option grant; neutral impact, minimal signal for RAPP investors.

The Form 4 discloses a standard director option award—10,925 options at $10.95. Such grants are common for early-stage biotech boards and represent less than 0.1% of outstanding shares (exact float not provided in filing). Because no shares were sold and the award vests over one year, dilution risk is remote and fully anticipated in equity-compensation plans disclosed at IPO. The strike price near prevailing market levels suggests no preferential pricing. Overall, the filing neither alters fundamental valuation nor provides predictive insight into future performance. Investors should monitor subsequent Form 4s for any share sales upon vesting, but the current event is operationally immaterial.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sanchez Ramiro

(Last) (First) (Middle)

RAPPORT THERAPEUTICS, INC.

99 HIGH STREET, SUITE 2100

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$10.95	06/17/2025		A		10,925		(1)	06/17/2035	Common Stock	10,925	$0	10,925	D

Explanation of Responses:

1. The shares underlying this option shall vest upon the earlier of (i) June 17, 2026 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

	/s/ Troy Ignelzi, Attorney-in-Fact	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many options were granted to Ramiro Sanchez in the RAPP Form 4?

10,925 stock options were granted.

What is the exercise price of the new RAPP director options?

Each option has an exercise price of $10.95.

When do the Ramiro Sanchez options vest?

They vest on 17 June 2026 or the next annual meeting, whichever comes first.

Did the director buy or sell any common shares of RAPP?

No common shares were bought or sold; the filing only reports an option grant.

What is the expiration date of the granted options?

The options expire on 17 June 2035.